Compare AU
Compare DAVA vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, shares and ETFs are a popular choice. Two options in the ASX are DAVA and DRUG. In this comparison, we'll delve into these options across various dimensions to help you make an informed investment decision.
Community Stats
DAVA | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 1 | 64 |
Median incremental investment | $2,993.50 | $882.72 |
Median investment frequency | Monthly | Monthly |
Median total investment | $5,981.92 | $1,967.19 |
Average age group | > 35 | 26 - 35 |
Key Summary
DAVA | DRUG | |
|---|---|---|
Strategy | DAVA.AX was created on 1999-06-10 by Dimensional. The fund's investment portfolio concentrates primarily on total market equity. The investment objective of the Trust is to provide long-term capital growth by gaining exposure to a diversified portfolio of Value Companies listed in Australia. | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | Dimensional Australian Value Trust - Active ETF (100 %) | BRL - BRAZILIAN REAL (0 %) AUD - AUSTRALIA DOLLAR (0 %) CHF - SWISS FRANC (0 %) |
Top 3 industries | Other (76.17 %) Communication Services (33.53 %) Health Care (23.66 %) | |
Top 3 countries | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) | |
Management fee | 0.336 % | 0.57 % |
Key Summary
DAVA | DRUG | |
|---|---|---|
Issuer | Dimensional | BetaShares |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | |
Asset class | ETF | ETF |
Management fee | 0.336 % | 0.57 % |
Price | $27.44 | $7.61 |
Size | N/A | $167.407 million |
10Y return | N/A | N/A |
Annual dividend/ distribution yield (5Y) | 0.87 % | 1.89 % |
Market | ASX | ASX |
First listed date | 18/08/2024 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
DAVA | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 1 | 64 |
Median incremental investment | $2,993.50 | $882.72 |
Median investment frequency | Monthly | Monthly |
Median total investment | $5,981.92 | $1,967.19 |
Average age group | > 35 | 26 - 35 |
Pros and Cons
DAVA | DRUG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
DAVA | DRUG |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Lower price growth | Higher price growth |
Lower distribution yield | Higher distribution yield |